Janssen Pharmaceutical: Akeega Gets FDA Approval to Treat Prostate Cancer Patients
August 11 2023 - 5:38PM
Dow Jones News
By Stephen Nakrosis
Janssen Pharmaceutical said Friday that the Food and Drug
Administration approved Akeega as a treatment for a specific type
of prostate cancer.
Akeega, or niraparib and abiraterone acetate, was approved as a
treatment for BRCA-positive metastatic castration-resistant
prostate cancer, the Johnson & Johnson unit said. About 10% to
15% of patients with mCRPC have BRCA gene alterations, making them
more likely to experience poor outcomes and a shorter survival
time, the company said.
The approval was based on results from a Phase 3 study. The
company said in BRCA-positive patients treated with Akeega plus
prednisone, 47% risk reduction was observed for radiographic
progression-free survival.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 11, 2023 17:23 ET (21:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Oct 2024 to Nov 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Nov 2023 to Nov 2024
